We try to answer a fundamental biological question: what drives cancers to evolve to become resistant to treatment? Our research is dedicated to studying bladder cancer as a model disease for dissecting the fundamental biological mechanisms that drive the evolution of human cancers. We are investigating the role of the APOBEC3 mutagenic enzymes which edit the genome of cancer cells and act as evolutionary drivers of drug-resistance. We use a broad range of experimental tools and models to understand their role in cancer evolution. Our group is uniquely positioned to improve the lives of bladder cancer patients by translating our discoveries to early-phase and first-in-human clinical trials thus truly fulfilling the vision of 'bench-to-bedside and back' precision medicine.
-Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nature Genetics, 2016
-Treatment resistance in urothelial carcinoma: an evolutionary perspective. Nature Reviews Clinical Oncology, 2018
-Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling, Nature Communications, 2018